Short Interest in Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) Expands By 24.5%

Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) was the target of a large increase in short interest in the month of January. As of January 15th, there was short interest totalling 1,370,000 shares, an increase of 24.5% from the December 31st total of 1,100,000 shares. Approximately 7.9% of the company’s shares are short sold. Based on an average trading volume of 9,200,000 shares, the short-interest ratio is currently 0.1 days.

Wall Street Analyst Weigh In

Several research analysts recently commented on SYRS shares. JMP Securities restated a “market perform” rating on shares of Syros Pharmaceuticals in a report on Wednesday, November 13th. HC Wainwright restated a “neutral” rating and issued a $1.00 price target (down previously from $6.00) on shares of Syros Pharmaceuticals in a report on Wednesday, November 13th. TD Cowen reiterated a “hold” rating on shares of Syros Pharmaceuticals in a research note on Wednesday, November 13th. StockNews.com initiated coverage on shares of Syros Pharmaceuticals in a research note on Saturday. They set a “sell” rating on the stock. Finally, Brookline Capital Management reiterated a “hold” rating on shares of Syros Pharmaceuticals in a research note on Wednesday, November 13th. One research analyst has rated the stock with a sell rating, four have issued a hold rating and one has assigned a buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $3.33.

Syros Pharmaceuticals Stock Performance

Shares of SYRS stock traded down $0.01 during mid-day trading on Monday, reaching $0.17. 969,274 shares of the company were exchanged, compared to its average volume of 1,794,598. Syros Pharmaceuticals has a fifty-two week low of $0.16 and a fifty-two week high of $7.96. The company has a market capitalization of $4.45 million, a P/E ratio of -0.05 and a beta of 1.30. The business’s 50 day simple moving average is $0.22 and its 200 day simple moving average is $1.73.

Syros Pharmaceuticals (NASDAQ:SYRS) last released its quarterly earnings results on Thursday, October 31st. The company reported ($0.68) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.76) by $0.08. During the same quarter last year, the company posted ($1.35) EPS. On average, analysts forecast that Syros Pharmaceuticals will post -2.94 EPS for the current year.

Insider Transactions at Syros Pharmaceuticals

In related news, Director Nancy A. Simonian sold 134,713 shares of the firm’s stock in a transaction that occurred on Monday, November 25th. The shares were sold at an average price of $0.27, for a total value of $36,372.51. Following the transaction, the director now owns 41,070 shares in the company, valued at approximately $11,088.90. This trade represents a 76.64 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Insiders own 12.26% of the company’s stock.

Institutional Trading of Syros Pharmaceuticals

An institutional investor recently bought a new position in Syros Pharmaceuticals stock. GSA Capital Partners LLP purchased a new position in shares of Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 15,905 shares of the company’s stock, valued at approximately $34,000. GSA Capital Partners LLP owned approximately 0.06% of Syros Pharmaceuticals at the end of the most recent quarter. 91.47% of the stock is currently owned by hedge funds and other institutional investors.

Syros Pharmaceuticals Company Profile

Syros Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors.